GILD

Gilead Sciences, Inc. News Headlines

$100.79
*  
0.49
0.48%
Get GILD Alerts
*Delayed - data as of Aug. 20, 2014  -  Find a broker to begin trading GILD now
Exchange: NASDAQ
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save stocks for next time
Viewing
Filtered By
Ordered By

J&J's Velcade in Focus at the European Hematology Association - Analyst Blog
6/17/2014 5:20:00 PM - Zacks.com

Vertex Pharmaceuticals Crumbles on Analyst Worries - Analyst Blog
6/17/2014 5:00:00 PM - Zacks.com

Novartis Submits Bexsero to FDA for Marketing Approval - Analyst Blog
6/17/2014 4:47:00 PM - Zacks.com

Glaxo's Promacta Holds Promise - Analyst Blog
6/17/2014 4:45:00 PM - Zacks.com

Ligand Pharma's LGD-6972 Positive in Phase I Study - Analyst Blog
6/17/2014 4:35:00 PM - Zacks.com

Valeant Receives FDA's Clearance for Restylane - Analyst Blog
6/17/2014 3:05:00 PM - Zacks.com

Celgene's Pomalyst Data at European Hematology Association Shows Promise - Analyst Blog
6/17/2014 1:40:00 PM - Zacks.com

Hepatitis C May Give A Big Boost To These Drug Stocks - If The FDA Approves
6/17/2014 1:32:00 PM - Seeking Alpha

Orexigen (OREX) in Focus: Stock Moves 7.5% Higher - Tale of the Tape
6/17/2014 9:46:00 AM - Zacks.com

Sequenom Inc. (SQNM) Soars: Stock Rises 9.2% - Tale of the Tape
6/17/2014 9:39:00 AM - Zacks.com

Gilead Sciences To Present At Wells Fargo Conference; Webcast At 10:00 AM ET
6/17/2014 9:00:00 AM - RTT News

Achillion Pharmaceuticals (ACHN) Jumps: Stock Up 20.9% - Tale of the Tape
6/17/2014 8:51:00 AM - Zacks.com

Strength Seen in bluebird bio, Inc. (BLUE) as Stock Shoots up 32.08% - Tale of the Tape
6/17/2014 8:44:00 AM - Zacks.com

Maxim's $22 Price Target On Achillion Is Far From Realistic
6/17/2014 3:33:00 AM - Seeking Alpha

Actelion's Selexipag Meets Primary Endpoint - Analyst Blog
6/16/2014 6:15:00 PM - Zacks.com

Celgene's Vidaza Disappoints in Phase III Study - Analyst Blog
6/16/2014 6:10:00 PM - Zacks.com

OncoMed's OMP-18R5 On Clinical Hold, Shares Down - Analyst Blog
6/16/2014 5:22:00 PM - Zacks.com

Agios Presents Data on AG-221 - Analyst Blog
6/16/2014 5:21:00 PM - Zacks.com

Karyopharm Therapeutics Skyrockets on Drug Trial News - Analyst Blog
6/16/2014 5:10:00 PM - Zacks.com

Novo Nordisk's Victoza 3 mg Positive in Phase III - Analyst Blog
6/16/2014 4:45:00 PM - Zacks.com

Sanofi's Diabetes Portfolio in Focus at American Diabetes Association Sessions - Analyst Blog
6/16/2014 4:30:00 PM - Zacks.com

Integra LifeSciences, Premier Ink 3-Year Purchase Deal - Analyst Blog
6/16/2014 2:50:00 PM - Zacks.com

AbbVie Gets Priority Review from FDA for HCV Treatment - Analyst Blog
6/16/2014 1:50:00 PM - Zacks.com

Gilead's HCV Combination Therapy Data Looks Promising - Analyst Blog
6/16/2014 11:40:00 AM - Zacks.com

Market Consensus For Gilead's Q2 Revenue At $5.3B Is $0.5B Light
6/16/2014 10:05:00 AM - Seeking Alpha